Summary
- Regardless of the company’s growing, diversified portfolio and pipeline of drugs, Antares stock continues to trade like it is a one-product company.
- Negative trial results for partnered drug Makena-subq and FDA approval of testosterone drug Jazenzo tipped Antares shares into freefall in March, falling over 25% from a recent high of $3.96.
- Antares stock continues to trade near $3 per share, about the same as it did 20 years ago.
- Antares represents significant value due in a large part to the strength of the company’s business model, which should gain recognition as 2019 unfolds.
During the 1992 presidential campaign, candidate Bill Clinton used the slogan “It’s the economy stupid” in the race with opponent George H.W. Bush. Due to a short recession during the time frame, the slogan proved to be prophetic to the final outcome of the election, with Bush suffering a painful defeat. It is likely that a similar slogan applying to the Antares Pharma (ATRS) business model will be just as relevant to the Antares story and business success.
